Loading
A phase 2 trial of Acalabrutinib, Rituximab in mantle cell lymphoma, run by AstraZeneca, now recruiting.
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain is a phase 2 interventional study registered as NCT07029737 by AstraZeneca, with 55 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-12-31. Interventions recorded: Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy. Conditions listed: Mantle-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Rituximab, Mantle cell lymphoma, AstraZeneca.
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/